Thrombotic thrombocytopenic purpura complicated with acute aortic dissection
A case report

Mei-Juan Huang, MM, Jin-Niu Deng, MB, Li-Li Gao, MD, PhD∗, Jian-Feng Zhou, MD, PhD

Abstract
Rationale: Thrombotic thrombocytopenic purpura (TTP) is a critical thrombotic microangiopathy involving multiple organs. To the best of our knowledge, there are no reports of TTP complicated by acute aortic dissection.
Patient concerns: We herein described a 53-year-old male with TTP who did not have a significant medical history. After immediate plasma exchange and glucocorticoid therapy, the patient’s clinical condition improved. However, the patient suddenly experienced chest pain with elevated blood pressure.
Diagnoses: Computed tomography angiography suggested acute type B aortic dissection.
Interventions: The patient was immediately transferred to the cardiac aortic surgery department for thoracic aortic endovascular repair.
Outcomes: The patient was discharged after successful thoracic aortic endovascular repair. Unfortunately, 3 months later, the patient experienced chest and back pain at home and died suddenly, possibly due to the recurrence of aortic dissection.
Lessons: Even if patients have no identifiable risk factors, physicians should be aware of this rare and life-threatening acute complication of TTP, which may have multiple causes, including preexisting connective tissue disease, abnormal blood pressure fluctuations, and increased risk of hemorrhage. Early identification and timely treatment of acute aortic dissection are critical for improving prognosis.
Abbreviations: AAD = acute aortic dissection, CT = computed tomography, CTA = computed tomography angiography, CTD = connective tissue disease, TEVAR = thoracic aortic endovascular repair, TTP = thrombotic thrombocytopenic purpura.
Keywords: acute aortic dissection, connective tissue disease, thoracic aortic endovascular repair, thrombotic thrombocytopenic purpura

1. Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease with 90% mortality and is characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, neurological abnormalities, fever, and renal insufficiency.[1] Inherited mutations in the ADAMTS13 gene or autoantibodies against ADAMTS13 contribute to the deficiency of ADAMTS13 activity, which leads to the formation of disseminated microvascular platelet thrombi that are attributed to unusually large multimers of von Willebrand factor that cannot be cleaved in the circulation. Acute aortic dissection (AAD) is a cardiovascular emergency that mainly arises from a tear in the aortic intima followed by cleavage formation and spread into the media, although it can also arise from spontaneous bleeding into the vessel wall and hematoma formation.[2] Typical symptoms of AAD include sudden sharp tearing in the chest or back pain, and some patients may have high blood pressure as the initial manifestation. Long-term arterial hypertension, connective tissue disorders, hereditary vascular disease, and vascular inflammation, such as autoimmune diseases, are common risk factors for AAD.[3,4] Here, we describe a patient with acute TTP who developed B aortic dissection during treatment and was discharged after successful thoracic aortic endovascular repair (TEVAR).
2. Case report

A 53-year-old Chinese male patient presented to our hospital with ecchymosis and edema for more than 2 months. Routine blood tests showed a hemoglobin level of 62 g/L and platelet count of $10 \times 10^9/L$. Suddenly, the patient appeared unconscious and recovered to normal approximately 3 hours later without any obvious abnormality on brain computed tomography (CT) and was then transferred to our hospital. This patient had no special medical history except for left leg trauma 30 years ago, and physical examination showed apathy, pale conjunctiva, and visible skin purpura. Laboratory tests indicated white blood cells $8.37 \times 10^9/L$; hemoglobin, 53 g/L; platelet count, $3 \times 10^9/L$; reticulocytes, 0.224 $\times 10^5/L$; total bilirubin 39.7 $\mu$mol/L, direct bilirubin 12.0 $\mu$mol/L, indirect bilirubin 27.7 $\mu$mol/L, lactate dehydrogenase, 1640 U/L, urea 18.75 mmol/L, creatinine 108 $\mu$mol/L (normal range 59-104 $\mu$mol/L), free hemoglobin (168 mg/L), and haptoglobin < 0.06 g/L. Direct Coombs test results were negative. Rheumatism tests showed that the antinuclear antibody nuclear particle type was 1:100, anti-SSA antibody was 7.1, and anti-SSB antibody was > 8.0. Platelet alloantibodies were positive, and platelet autoantibodies were negative. Routine urine tests suggested urinary occult blood 3+, urine protein ±, blood urea 24.82 mmol/L, and creatinine 138 $\mu$mol/L. It was easy to see schistocytes on his peripheral blood smear, accounting for 21% of the cells. Bone marrow cytology was characterized by megakaryocytic hyperplasia, maturation disorder, and myeloid hyperplasia. The patient had intermittent fever up to 38°C, intermittent disturbance of consciousness, and transient renal dysfunction during the hospital stay. Based on the above clinical manifestations and laboratory findings, the patient was diagnosed with thrombotic thrombocytopenic purpura with a classic “pentad”, including thrombocytopenia, neurological involvement, microangiopathic hemolytic anemia (elevated indirect bilirubin and reticulocyte, presenting schistocytes on peripheral blood smear), renal impairment and fever, which was likely related to connective tissue disease (CTD). Before measuring the ADAMTS13 activity level, we calculated the PLASMIC score in this patient to predict ADAMTS13 activity.[5] This score includes 7 indicators, with higher scores indicating more likely TTP. The patient had a score of 5 (platelet count < $30 \times 10^9$ per L, hemolysis variable, no active cancer, no history of solid organ or stem cell transplantation, creatinine < 2.0 mg/dL). Before we collected plasma samples for ADAMTS13 activity and inhibitors, he had been transfused with fresh frozen plasma and treated with glucocorticoids. Although the result of ADAMTS13 activity detected by a fluorescence energy transfer assay was 16%, experts with experience in management of TTP still believed that the patient should be diagnosed with TTP because of typical clinical manifestations and ADAMTS13 inhibitor positivity.[6]

He was treated with daily plasma exchange (9 times) at 1.0 $\times$ patient plasma volume until the platelet count recovered to normal and was maintained for at least 2 days, and his clinical symptoms were relieved. In addition, the patient received high-dose glucocorticoids (methylprednisolone 500 mg/d) for 5 days, which was then gradually reduced to 48 mg/d; N-acetylcysteine for 17 days, and 3 once-weekly doses of rituximab (375 mg/m²) (Fig. 1A). Lactate dehydrogenase gradually decreased, and ADAMTS13 activity gradually increased (Fig. 1A). Her platelet count returned to normal (Fig. 1B). On the 11th day after admission, the patient’s blood pressure suddenly increased to 187/98 mm Hg, mainly at night and in the morning, without any other discomfort (Fig. 1B). Ambulatory blood pressure monitor-
3. Discussion

To our knowledge, this is the first report of TTP complicated by AAD. It is difficult to clarify the underlying mechanisms of AAD in patients without risk factors. Based on the abnormal antinuclear antibody (nuclear particle type) 1:100 and increased anti-SSA antibody that we observed, we speculated that it may be associated with underlying CTD. The episodes of acquired TTP are often accompanied by or triggered by other diseases, including autoimmune disorders, drugs, cancer, surgery, infection, transplantation, and pregnancy.\textsuperscript{[7,8]} The presence of autoantibodies against ADAMTS13 reveals immune dysfunction in patients with acquired TTP.\textsuperscript{[7]} A variety of CTDs that are reported to be concurrent or secondary to TTP are also related to autoimmune diseases, including systemic lupus erythematosus, mixed connective tissue disease, and systemic scleroderma.\textsuperscript{[9–11]} It is estimated that 9% of patients with TTP have a medical history of CTD, and 21.5% of patients with TTP may have preexisting, co-existing, or subsequent autoimmune diseases. The appearance of anti-SSA antibodies or anti-dsDNA antibodies at TTP diagnosis has been closely related to autoimmune disorders during follow-up.\textsuperscript{[12]} Moreover, fragmentation of elastic fibers and disturbance of smooth muscle cells in the aortic intima of patients with CTD lead to an abnormal mechanical structure of the aortic wall and increased fragility of the vessel wall.\textsuperscript{[13]} Vascular damage caused by various connective tissue diseases further leads to aortic dissection or other vascular diseases.

When patients present with thrombocytopenia and microangiopathic hemolysis, TTP should be suspected, and daily plasma exchange should be performed immediately until a clinical response is obtained.\textsuperscript{[14]} Glucocorticoids are also recommended. However, long-term use of glucocorticoids may lead to cardiovascular complications, accelerating atherosclerosis and resulting in aortic aneurysmal enlargement, especially in the context of potential vasculitis and vascular involvement in CTD or TTP.\textsuperscript{[15]} This patient had no cardiovascular or endocrine disease, and his blood pressure was normal upon admission. However, the patient had an intermittent nocturnal blood pressure increase before AAD, which may be related to glucocorticoid effects or early manifestations of aortic dissection. Hemodynamic abnormalities further promote the occurrence of aortic dissection on the existing structural abnormalities of the arterial wall. In addition, patients with thrombotic thrombocytopenia may have a tendency for spontaneous hemorrhage in the aorta. USUI and Tsai reported a patient with AAD with idiopathic thrombocytopenic purpura, neither of whom had risk factors for dissection, suggesting that dissection may be associated with an increased risk of spontaneous bleeding in the aortic wall caused by thrombocytopenia.\textsuperscript{[16,17]} However, transient thrombocytopenia in this patient before AAD may be ascribed to consumptive bleeding initiated by AAD because the patient’s platelet count remained normal for many days and quickly returned to normal after the operation.

Imaging examinations are essential not only to diagnose AAD in a timely manner but also to display the localization of tears, determine the type of AAD, and guide therapeutic intervention. Noninvasive CT and contrast-enhanced CTA are the most commonly used methods. According to the Stanford system, aortic dissection is divided into 2 types: acute type A dissection, involving the ascending aorta, requires urgent surgical treatment, because the mortality rate increases by 1% to 2% per hour after the onset of symptoms, and if untreated, 50% of patients die within 1 week, Stanford type B mainly involves the descending aorta at the distal end of the left subclavian artery, and medical management remains the preferred treatment option for uncomplicated acute type B dissection.\textsuperscript{[18]} TEVAR to eliminate the false lumen and ensure true lumen by stent-grafting to seal the rupture is recommended for complicated acute type B aortic dissection.\textsuperscript{[18]} However, some authors believe that prophylactic repair of acute type B dissection can also benefit high-risk patients and prevent late complications.\textsuperscript{[18–21]} Once diagnosed with Stanford type B aortic dissection, the patient was immediately transferred to the cardiac aortic surgery department for TEVAR treatment.
4. Conclusion
In conclusion, early diagnosis of AAD in TTP remains a challenge for clinicians. We describe the first case of TTP complicated with acute dissection type B that occurred during TTP treatment, hoping to raise awareness among clinicians about this rare complication. When back pain or thoracoabdominal pain and unexplained hypertension occur in patients with TTP, aortic dissection should be suspected, and CTA examination should be performed promptly. It is necessary to monitor blood pressure closely and control it in a timely manner during glucocorticoid treatment. Whether TTP is a risk factor for spontaneous bleeding within the aorta and the relationship between TTP and AAD is still worthy of further discussion.

Author contributions
Conceptualization: Jin-Niu Deng.
Supervision: Jian-Feng Zhou.
Writing – original draft: Mei-Juan Huang.
Writing – review & editing: Li-Li Gao.

References
[1] George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematol Am Soc Hematol Educ Program 2012;2012:604–9.
[2] Nienaber CA, Clough RE. Management of acute aortic dissection. Lancet 2015;385:800–11.
[3] Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 2000;283:897–903.
[4] Nienaber CA, Powell JT. Management of acute aortic syndromes. Eur Heart J 2012;33:26–35b.
[5] Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 2017;4:e137–64.
[6] Tang N, Wang X, Li D, Sun Z. Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients. Thromb Res 2018;172:9–13.
[7] Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017;15:312–22.
[8] Joly BS, Coppo P, Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol 2019;12:383–95.
[9] Suzuki E, Kanno T, Asano T, et al. Two cases of mixed connective tissue disease complicated with thrombotic thrombocytopenic purpura. Fukushima J Med Sci 2013;59:49–55.
[10] Viner M, Murakhovskaya I. A rare combination of thrombotic thrombocytopenic purpura and antiphospholipid syndrome. Blood Coagul Fibrinolysis 2017;28:411–5.
[11] Bamidele OF, Akintayo RO, Bojuwove MO, Alabi TO, Akintayo FC, Bamidele OV. Thrombotic thrombocytopenic purpura as the first presentation in systemic lupus erythematosus. Reumatologia 2018;56:268–70.
[12] Rozit M, Landais M, Desprez J, et al. Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltimore) 2013;94:e1598.
[13] Marque V, Kieffer P, Gayraud B, Lartaud-Idjouadiene I, Ramirez F, Atkinson J. Aortic wall mechanics and composition in a transgenic mouse model of Marfan syndrome. Arterioscler Thromb Vasc Biol 2001;21:1184–9.
[14] Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017;129:2836–46.
[15] Ohara N, Miyata T, Kurata A, Oshiro H, Sato O, Shigematsu H. Ten years’ experience of aortic aneurysm associated with systemic lupus erythematosus. Eur J Vasc Endovasc Surg 2000;19:288–93.
[16] Usui A, Kawamura M, Hibi M, Yoshiida K, Murakami F, Iwase J. Emergency aortic arch replacement in a patient with idiopathic thrombocytopenic purpura. Surg Today 1996;26:828–30.
[17] Tsai J, Sherman SC. Aortic dissection in a young man with immune thrombocytopenic purpura. J Emerg Med 2005;28:285–8.
[18] Nienaber CA, Kische S, Rousseau H, et al. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 2013;6:407–16.
[19] Winnekervist A, Lockowandt U, Rasmussen E, Radegran K. A prospective study of medically treated acute type B aortic dissection. Eur J Vasc Endovasc Surg 2006;32:349–55.
[20] Fattori R, Montgomery D, Lovato L, et al. Survival after endovascular therapy in patients with type B aortic dissection: a report from the International Registry of Acute Aortic Dissection (IRAD). JACC Cardiovasc Interv 2013;6:876–82.
[21] Hughes GC, Andersen ND, McCann RL. Management of acute type B aortic dissection. J Thorac Cardiovasc Surg 2013;145:S202–7.